High frequency of cutaneous eruptions within the first year after allogeneic hematopoietic stem cell transplantation

Abstract

AbstractBackgroundThe diagnosis and management of eruptions after hematopoietic cell transplantation (HCT) is a challenge due to their atypical clinical presentation and the biology biased by immunosuppression and graft. The diagnosis is therefore based on multiple grounds. Few studies have focused on the occurrence of a skin rash during the first year of transplantation.ObjectivesTo assess the frequency of rashes in this period, as well as their differential diagnosis and multidisciplinary management.MethodsWe performed a retrospective monocentric descriptive study in the Department of Blood Diseases of Lille University Hospital. All patients who received allogeneic HCT between January 1, 2018, and December 31, 2019, were included.ResultsWe included 196 patients with allogeneic HCT. Of these, 89 (45.4%) presented a skin rash during the first year after transplantation. Among them, 78.7% were diagnosed with acute graft versus host disease (GVHD), 6.7% chemotherapy toxicity, 4.5% chronic GVH, 2.2% of infectious origin and 1.1% drug hypersensitivity. The outcome was mainly favourable (74.2% experienced resolution). A skin biopsy was performed in 9% of cases. Viral polymerase chain reactions (PCRs) were positive in 7.1% of tested patients.ConclusionsOur study revealed a high frequency of skin rashes in stem cell transplant patients, thus justifying the multidisciplinary management of these high‐risk patients, which require both dermatological and haematological early expert assessment.